Alpha L-Iduronidase (IDUA or EC 188.8.131.52) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The latest report Alpha L-Iduronidase Pipeline Review, H1 2017, outlays comprehensive information on the Alpha L-Iduronidase (IDUA or EC 184.108.40.206) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/323690 .
Alpha L-Iduronidase (IDUA or EC 220.127.116.11) Alpha L-iduronidase is an enzyme encoded by IDUA gene. It hydrolyzes the terminal alpha-L-iduronic acid residues of two glycosaminoglycans, dermatan sulfate and heparan sulfate. Mutations in this gene that result in enzymatic deficiency lead to the autosomal recessive disease mucopolysaccharidosis type I (MPS I). The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Genetic Disorders which include indications Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ).
Furthermore, this report also reviewsalso reviews key players involved in Alpha L-Iduronidase (IDUA or EC 18.104.22.168) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Browse the full report @ http://www.orbisresearch.com/reports/index/alpha-l-iduronidase-idua-or-ec-3-2-1-76-pipeline-review-h1-2017 .
The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 22.214.171.124)
The report reviews Alpha L-Iduronidase (IDUA or EC 126.96.36.199) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 188.8.131.52) targeted therapeutics and enlists all their major and minor projects
The report assesses Alpha L-Iduronidase (IDUA or EC 184.108.40.206) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 220.127.116.11) targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 18.104.22.168)
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 22.214.171.124) development landscape
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/323690 .
Bioasis Technologies Inc
Sangamo Therapeutics Inc
For any enquires before buying, connect with us @ firstname.lastname@example.org
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact email@example.com